Health-related quality of life in patients with hemoglobinopathies

Hematology (United States)

Volumn 2012, Issue 1, 2012, Pages 284-289

  Panepinto, Julie A ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; CHILD; CHRONIC DISEASE; HEALTH STATUS; HEMOGLOBINOPATHY; HUMAN; INFANT; METHODOLOGY; PRESCHOOL CHILD; PSYCHOLOGICAL ASPECT; PSYCHOMETRY; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; SICKLE CELL ANEMIA; SICKNESS IMPACT PROFILE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANEMIA, SICKLE CELL; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; HEALTH STATUS; HEMOGLOBINOPATHIES; HUMANS; INFANT; PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES; SICKNESS IMPACT PROFILE; TREATMENT OUTCOME;

EID: 84879337332     PISSN: 15204391     EISSN: 15204383     Source Type: Journal    
DOI: 10.1182/asheducation.v2012.1.284.3798319     Document Type: Article

References (35)

1. DeSalvo KB, Bloser N, Reynolds K, He J, Muntner P. Mortality prediction with a single general self-rated health question. A meta-analysis. J Gen Intern Med. 2006; 21 (3): 267-275.
2. Dominick KL, Ahern FM, Gold CH, Heller DA. Relationship of health-related quality of life to health care utilization and mortality among older adults. Aging Clin Exp Res. 2002; 14(6): 499-508.
3. Velikova G, Booth L, Smith AB, et al. Measuring quality of life in routine oncology practice improves communication and patient well-being: A randomized controlled trial. J Clin Oncol. 2004; 22(4):714-724.
4. Panepinto JA, Pajewski NM, Foerster LM, Hoffmann RG. The performance of the PedsQL generic core scales in children with sickle cell disease. J Pediatr Hematol Oncol. 2008; 30(9):666- 673.
5. Panepinto JA, O'Mahar KM, DeBaun MR, Rennie KM, Scott JP. Validity of the child health questionnaire for use in children with sickle cell disease. J Pediatr Hematol Oncol. 2004; 26(9): 574-578.
6. McClellan CB, Schatz J, Sanchez C, Roberts CW. Validity of the Pediatric Quality Of Life Inventory for youth with sickle cell disease. J Pediatr Psychol. 2008; 33(10):1153-1162.
7. Dampier C, Lieff S, LeBeau P, et al. Health-related quality of life in children with sickle cell disease: A report from the Comprehensive Sickle Cell Centers Clinical Trial Consortium. Pediatr Blood Cancer. 2010; 55(3):485-494.
8. Asnani MR, Lipps GE, Reid ME. Validation of the SF-36 in Jamaicans with sickle-cell disease. Psychol Health Med. 2009; 14 (5): 606-618.
9. Asnani M, Lipps G, Reid M. Component structure of the SF-36 in Jamaicans with sickle cell disease. West Indian Med J. 2007; 56(6):491-497.
10. Werner EM, Treadwell M, Hassell K, Keller S, Levine R. Sickle cell disease health-related quality of life questionnaire project [abstract]. Blood (ASH Annual Meeting Abstracts). 2006; 108(11):3339.
11. Panepinto JA, Torres S, Varni JW. Development of the PedsQL sickle cell disease module items: qualitative methods. Qual Life Res. 2012; 21(2):341-357.
12. DeWalt DA. PROMIS Pediatrics: Longitudinal Validation and Linking Pediatric and Adult Item B. Available from: http://projectreporter.nih.gov/project-info-description.cfm?aid-7944072&icde-8023496. Accessed June 12, 2012.
13. Panepinto JA, Bonner M. Health-related quality of life in sickle cell disease: Past, present, and future. Pediatr Blood Cancer. 2012; 59 (2): 377-385.
14. Ismail A, Campbell MJ, Ibrahim HM, Jones GL. Health related quality of life in Malaysian children with thalassaemia. Health Qual Life Outcomes. 2006; 4: 39.
15. Sobota A, Yamashita R, Xu Y, et al. Quality of life in thalassemia: A comparison of SF-36 results from the thalassemia longitudinal cohort to reported literature and the US norms. Am J Hematol. 2011; 86(1):92-95.
16. Torcharus K, Pankaew T. Health-related quality of life in Thai thalassemic children treated with iron chelation. Southeast Asian J Trop Med Public Health. 2011; 42(4):951-959.
17. Cheuk DKL, Mok ASP, Lee ACW, et al. Quality of life in patients with transfusion-dependent thalassemia after hematopoietic SCT. Bone Marrow Transplant. 2008; 42(5):319-327.
18. Caocci G, Pisu S, Argiolu F, et al. Decision-making in adult thalassemia patients undergoing unrelated bone marrow transplantation: quality of life, communication and ethical issues. Bone Marrow Transplant. 2006; 37(2):165-169.
19. Kelly MJ, Pennarola BW, Rodday AM, Parsons SK. Healthrelated quality of life (HRQL) in children with sickle cell disease and thalassemia following hematopoietic stem cell transplant (HSCT). Pediatr Blood Cancer. 2012; 59 (4): 725- 731.
20. Brandow AM, Brousseau DC, Pajewski NM, Panepinto JA. Vaso-occlusive painful events in sickle cell disease: impact on child well-being. Pediatr Blood Cancer. 2010; 54(1):92-97.
21. Thornburg CD, Calatroni A, Panepinto JA. Differences in health-related quality of life in children with sickle cell disease receiving hydroxyurea. J Pediatr Hematol Oncol. 2011; 33(4): 251-254.
22. Thornburg CD, Dixon N, Burgett S, et al. A pilot study of hydroxyurea to prevent chronic organ damage in young children with sickle cell anemia. Pediatr Blood Cancer. 2009; 52(5): 609-615.
23. Ballas SK, Barton FB, Waclawiw MA, et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health Qual Life Outcomes. 2006; 4: 59.
24. van Beers EJ, van Tuijn CF, Nieuwkerk PT, Friederich PW, Vranken JH, Biemond BJ. Patient-controlled analgesia versus continuous infusion of morphine during vaso-occlusive crisis in sickle cell disease, a randomized controlled trial. Am J Hematol. 2007; 82(11):955-960.
25. Revicki DA, Gnanasakthy A, Weinfurt K. Documenting the rationale and psychometric characteristics of patient reported outcomes for labeling and promotional claims: The PRO Evidence Dossier. Qual Life Res. 2007; 16(4):717-723.
26. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials. 1989; 10(4):407-415.
27. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol. 1994; 47(1):81-87.
28. Crosby RD, Kolotkin RL, Williams GR. Defining clinically meaningful change in health-related quality of life. J Clin Epidemiol. 2003; 56(5):395-407.
29. Brozek JL, Guyatt GH, Schunemann HJ. How a well-grounded minimal important difference can enhance transparency of labelling claims and improve interpretation of a patient reported outcome measure. Health Qual Life Outcomes. 2006; 4: 69.
30. Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR. Methods to explain the clinical significance of health status measures. Mayo Clin Proc. 2002; 77 (4): 371-383.
31. Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE Jr. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum. 2000; 43(7): 1478-1487.
32. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: The remarkable universality of half a standard deviation. Med Care. 2003; 41(5):582-592.
33. Basch E, Iasonos A, Barz A, et al. Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy. J Clin Oncol. 2007; 25(34):5374-5380.
34. Davis K, Yount S, Del Ciello K, et al. An innovative symptom monitoring tool for people with advanced lung cancer: A pilot demonstration. J Support Oncol. 2007; 5 (8): 381-387.
35. Takeuchi EE, Keding A, Awad N, et al. Impact of patientreported outcomes in oncology: A longitudinal analysis of patient-physician communication. J Clin Oncol. 2011; 29 (21): 2910-2917.